Biohealth Innovation
Click here to view original article »
 

You're receiving this newsletter because of your interest in BioHealth Innovation
Having trouble viewing this email? View it in your browser.

Jan 19, 2016
NEWS
 
ABOUT US PROGRAMS PARTNERS CLIENTS NEWS EVENTS CONTACT
 
NEWS
 
EVENTS
 
JOBS
 
 
 
Medigene AG announces key Management Changes; BHI Board Member Dave Lemus appointed Chief Operating Officer of Medigene AG and Chief

Medigene AG (Frankfurt Stock Exchange: MDG1) announced today that the Supervisory Board has resolved important changes and additions to the senior management team to better align the organisational structure with the strategic goals of the company in immuno-oncology and to expand Medigene's presence in the United States. The Supervisory Board has appointed Prof Dolores Schendel as the new Chief Executive Officer of the company, with effect from 1 February 2016. Prof Schendel joined Medigene's Executive Board as Chief Scientific Officer in May 2014. She was co-founder of Trianta Immunotherapy GmbH (now Medigene Immunotherapies GmbH), which was acquired by Medigene at the beginning of 2014 and whose platforms are the basis of Medigene's scientific strategy.

Dave Lemus, Vice Chairman of the Supervisory Board of the company, will transition with effect from 1 January 2016 to the Executive Management Board. He will assume the newly created position of the Chief Operating Officer. In addition, Mr. Lemus will be Chief Executive Officer of the US subsidiary Medigene Inc.

READ MORE
 
 
 
 
BHI Seeking Financial Analyst

The Financial Analyst plays a key role in supporting the strategic financial goals of BHI Management Inc. (BHIM) and its parent company, BioHealth Innovation, Inc. (BHI). This position reports to the President of BHIM. The Financial Analyst influences BHIM through providing information, intelligence and insights which influence BHIM portfolio investment decisions. Key responsibilities of the position can be summarized as follows:

READ MORE
New Germantown cancer immunotherapy biotech launches with $67 million venture round - Washington Business Journal

Germantown startup NextCure Inc. has raised $67 million in Series A financing for a plan to commercialize the work of a scientist credited with discovering a key pathway for how cancer drugs harness the immune system, it was announced Wednesday.

READ MORE
Vtesse, Inc. Announces FDA's Granting of Breakthrough Therapy Designation for VTS-270 in Niemann-Pick...

Vtesse, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted its drug candidate, VTS-270 for treatment of Niemann-Pick Type C1 Disease (NPC), Breakthrough Therapy designation status. Both the FDA and the European Medicines Agency (EMA) had previously granted Orphan Drug status to VTS-270, which is currently in a pivotal Phase 2b/3 clinical trial.

READ MORE
Emergent BioSolutions Receives Favorable IRS Private Letter Ruling in Connection With its Planned Biosciences Business Spin-Off - NASDAQ.com

Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has received a favorable private letter ruling from the Internal Revenue Service related to the planned spin-off of its biosciences business. Subject to its terms, the ruling confirms that certain aspects of the planned transaction, including those related to the qualification of the business as an active trade or business, will not preclude the spin-off from qualifying as tax-free to Emergent and its stockholders.

READ MORE
Sucampo Pharma (SCMP) Enters Option Agreement to License CPP-1X/Sulindac Product in North America

Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq: SCMP) announced an option and collaboration agreement under which Cancer Prevention Pharmaceuticals, Inc. (CPP) has granted Sucampo the sole option to acquire an exclusive license to commercialize CPP-1X/sulindac combination product in North America. This product is currently in a Phase 3 clinical trial for the treatment of familial adenomatous polyposis (FAP).

READ MORE
Deloitte and AT&T Partner to Accelerate Adoption of Smart City Technology

Deloitte today announced a strategic alliance agreement with AT&T aimed at accelerating the adoption of smart city technology across U.S. cities. The telco and global management consultancy, along with several other hand-picked alliance members, strive to enhance livability and improve the efficiencies of local governments through optimal use of today's technology.

READ MORE
OriGene Technologies Awarded Phase II SBIR Contract to Develop High-Affinity, Anti-Peptide Monoclonal Antibodies for SISCAPA Assays

OriGene Technologies, Inc. (OriGene), a leading manufacturer of high quality antibodies and gene-centric tools, announced today that they have been awarded a Phase II SBIR contract from the National Cancer Institute (NCI) to develop high-affinity, anti-peptide antibodies for mass-spectrometry-based serum biomarker detection/ quantification assays.

READ MORE
Here are the top venture capital recipients in Maryland through the first 9 months of 2015 - Baltimore Business Journal

As usual, we bring you the top five entries from our most recent list. This week, it's the top venture capital recipients in Maryland, based on funding received between the first and third quarters of 2015.

READ MORE
BioIT News: Selected Top 50 Tech Company by Insights Success magazine

"BioIT Solutions of Silver Spring, Maryland has been selected as one of the 50 Most Valuable Tech Companies by Insights Success magazine in their December issue. We are the only company in the list focused on the biotechnology industry."

READ MORE
Roche's investment in tech companies - Business Insider

A cancer startup just raised millions in a funding round led by a pharmaceutical giant.

That could be the sign of bigger things to come.

READ MORE
The East Coast City That's Becoming a Surprising Hub for Tech Startups - Inc.com

Baltimore, by a curious mixture of geographic positioning, educated talent, proximity to pork, and determined capital, is poised to become a crucial part of the East Coast technology cluster.

READ MORE
Under Armour's collaboration with IBM Watson provide big data insights to advance connected fitness approach - MedCity NewsMedCity News

Under Armour’s partnership with IBM Watson is the latest in a series of announcements from the consumer health and fitness business that illustrate how the company is thinking about big data applications not only to provide timely, helpful insights on athletic training to a customer base of 180 million but also how to get them to buy more gear.

READ MORE
Pursuing or Advancng Your Career in Tech Transfer and Business Development in 2016 - T2 Speakers Series - Jan 13

What is technology transfer / business development and what are the career opportunities in the field? What are the skills required and how does one acquire them? How can an scientist start a non-traditional career such as this? These are the questions to be answered in this presentation from two former bench scientists from the National Cancer Institute.

READ MORE
NEXT WEEK! Join BioBuzz & JHU in Gaithersburg on 1/21

Thursday January 21, 2016 from 5:00 PM to 7:00 PM EST

Johns Hopkins Montgomery County Campus is also a site for the popular Osher Lifelong Learning Institute. Geared toward retirees, these non-credit classes cover topics including opera, literature, history, politics and more.

The campus is home to approximately 35 research companies and entrepreneurs. Scientists on campus are studying cervical cancer, Alzheimer's disease, cell therapy, proteins and other health issues. Other companies focus on technology, medical devices and consulting services. The Rockville Science Center's administrative offices are located here. Start-up companies, second-stage businesses and more established companies are welcome.

READ MORE
The definitive guide to the J.P. Morgan Healthcare Conference - MedCity News

Ah. Another January, another J.P. Morgan Healthcare Conference — where this year’s biggest biopharma deals are just a cocktail and a handshake away. As swaths of C-suite execs descend upon San Francisco, here’s an overview of some of the ideas we expect to see in motion at the conference (cattle yard) this week:

READ MORE
Hopkins grad student named to Forbes' '30 Under 30' list - Baltimore Sun

Guy Marcus, a 24-year-old Ph.D. candidate in physics at the Johns Hopkins University, is one of 30 young scientists named to Forbes magazine's annual "30 Under 30" list.

READ MORE
Health care entrepreneur, Johns Hopkins graduate earns 'Forbes' distinction | Hub

David Narrow, who graduated from Johns Hopkins University in 2013 with a master's degree in biomedical engineering, has been named one of Forbes magazine's "30 Under 30" notable entrepreneurs in the health care industry.

Narrow, 25, is the CEO of Sonavex, a company that works to improve outcomes for surgical patients by providing clinicians cutting-edge visualization through the use of imaging technology. Sonavex is presently based in North Baltimore and is part of FastForward at Johns Hopkins Technology Ventures, a business accelerator program that supports startup companies.

READ MORE
Dana-Farber Spinout Grabs $73M, Plus Big Roche Deal, To Craft New Class Of Cancer Drugs - Forbes

Billions of dollars have been made from cancer drugs that inhibit the ubiquitin-proteasome system, otherwise known as the cellular garbage dump. By turning off the cell’s garbage disposal system, these drugs enable proteins to build up to a point where malignant cells commit suicide.

READ MORE
The 10 edgiest innovation ideas of 2016 - The Washington Post

At the end of every year, Edge reaches out to the smartest people on the planet and asks them a single question in an attempt to find the ideas and concepts that are changing the world of science. This year’s two-part question was: “What do you consider the most interesting recent [scientific] news? What makes it important?”

READ MORE
NASA, Carfax and University of Maryland draw high ratings from employees - Washington Business Journal

Do you work in Greater Washington and love your employer? Then you probably work at a federal agency. We asked Glassdoor, a job-recruiting site that allows employees to anonymously grade their company and their CEO, to crunch the numbers to find out who the most-liked employers are in Greater Washington. We recently compiled a list of most-liked CEOs, too.

READ MORE
The FDA can single-handedly reduce drug price-gouging. Why is it waiting? - LA Times

The crisis in soaring drug prices has produced not merely a new class of public enemies to skewer -- step forward, Martin Shkreli! -- but the best evidence yet that the nation's healthcare regulatory priorities are out of whack.

READ MORE
NATIONAL INSTITUTES OF HEALTH WebEx Enterprise Site

Tuesday, January 12, 2016 2:00 pm

When developing a new drug or technology, innovators are generally focused on achieving regulatory approval. But often they don’t spend enough time considering how the product will be paid for once it is approved. This NHLBI Small Biz Hangout will focus on basic components of reimbursement that every innovator needs to understand—coverage, coding, and payment. Attendees will hear guidance on how to implement an effective reimbursement strategy while their product is still in development.

READ MORE
Crews Serves Gaithersburg-Germantown Chamber of Commerce Board of Directors - News - Johns Hopkins University Montgomery County Campus

Barbara Crews, assistant executive director for community relations at the Johns Hopkins University Montgomery County Campus, has been appointed to an executive committee position with the Gaithersburg-Germantown Chamber of Commerce board of directors.

Crews will serve a yearlong term as vice chair for member recruitment and retention. In this role, she will help the chamber recruit new members and retain existing ones. She will help existing members get the most out of their memberships by engaging them in chamber activities.

READ MORE
Biopharma's top brass forms new immunotherapy coalition - MedCity News

We’re one step closer to open-source collaboration in the life sciences – and could come a hell of a lot closer to completely revolutionizing cancer treatment – thanks to a promising new alliance formed by the top brass in biopharma.

Meant to accelerate the potential of immunotherapy in treating cancer, The National Immunotherapy Coalition has just been launched by leaders from Amgen, Celgene, GlaxoSmithKline, Merck, and NantWorks – along with Independence Blue Cross and many others. Here’s why:

READ MORE
Jonathan Aberman: It’s time to overcome our self-esteem problem - The Washington Post

Our region’s business community has a self-esteem problem. We nod shamefully when we are told we depend on government dollars for success.

Wrong.

READ MORE
Illumina Jumps into Cancer Screening with $100 Million Spin-off Grail | MIT Technology Review

The world’s largest DNA sequencing company says it will form a new company to develop blood tests that cost $1,000 or less and can detect many types of cancer before symptoms arise.

Illumina, based in San Diego, said its blood tests should reach the market by 2019, and would be offered through doctors’ offices or possibly a network of testing centers.

READ MORE
ETC names new AccelerateBaltimore class, adds an additional investment - Baltimore Business Journal

Six startups have been selected for the Emerging Technology Centers’ AccelerateBaltimore program and one will receive an extra investment of $100,000. Now in its fifth year, AccelerateBaltimore is a four month program that aims to help promising startup companies come closer to bringing their products or services to market. The program is backed by $170,000 from the Abell Foundation. The money largely goes toward the $25,000 award given to each participating company.

READ MORE
Accelerator Corporation Launches First Startup in New York City Portfolio - FierceBiotech

Accelerator Corporation, a leading life science investment and management firm, today announced the Series A financing of Petra Pharma Corporation to develop small molecule inhibitors for the treatment of cancer and metabolic diseases in alliance with Weill Cornell Medicine. The investors participating in the $48 million Series A investment in Petra Pharma include Accelerator New York's investment syndicate partners: AbbVie, Alexandria Venture Investments, ARCH Venture Partners, Eli Lilly and Company, Harris & Harris Group, Inc., Innovate NY Fund, Johnson & Johnson Innovation – JJDC, Inc., The Partnership Fund for New York City, Pfizer Venture Investments, Watson Fund and WuXi PharmaTech.

READ MORE
6 Reasons Innovation is a Survival Skill - Innovation Excellence

Many articles these days talk about reasons why companies should consider innovation as a core discipline. A quick Google search on “why innovate” produces 23,600,000 results. There is a plethora of opinions regarding innovation and why it is important. Competition is usually one of the reasons but not the only one, especially when looking how the world will be in the near future. Innovation becomes a critical survival skill when looking at predictions for how we will live, work, and communicate as early as 2020.

READ MORE
AT&T to open innovation center at Texas Medical Center - Houston Chronicle

AT&T next month will open a center focused on digital health innovations within the Texas Medical Center's state-of-the-art Innovation Institute, the communications giant announced on Tuesday.

READ MORE
 
 
 
 

EVENTS

 

JOBS

 
     
 

Home | About BHI | BHI News | Programs | Partners | Contact
Copyright © BioHealth Innovation 2012
All Rights Reserved. 
22 Baltimore Road Rockville, MD 20850
Subscribe

 
 
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.